When was Tubulis Technologies founded?

Tubulis Technologies was founded in 2015.

Where is Tubulis Technologies located?

Tubulis Technologies is headquartered in Munich, Germany.

Who is the current CEO of Tubulis Technologies?

Dominik Schumacher of Tubulis Technologies. They have also founded 1 company.

Which legal entities is Tubulis Technologies associated with?

Tubulis Technologies is associated with Tubulis GmbH and 1 other.

How many employees does Tubulis Technologies have?

As of Aug 31, 2026, the latest employee count at Tubulis Technologies is 77.

Is Tubulis Technologies a funded company?

Tubulis Technologies is a funded company, having raised a total of $615M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round.

When was the latest funding round of Tubulis Technologies?

Tubulis Technologies' latest funding was a $***** Series C round on Oct 15, 2025, with participation from 16 investors.

Where does Tubulis Technologies rank among its competitors?

Tubulis Technologies ranks 109th amongst 3386 active competitors, of which 1136 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Tubulis Technologies?

Tubulis Technologies' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Tubulis Technologies - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Is Tubulis Technologies an acquired company?

Tubulis Technologies got acquired by Gilead on Apr 07, 2026.

Tubulis Technologies is an acquired company based in Munich (Germany), founded in 2015 by Dominik Schumacher and Jonas Helma-Smets. It operates as a Developer of antibody-drug conjugates for the treatment of cancer. Tubulis Technologies has raised $615M in funding from investors like Venrock, Life Sciences Partners and BioMedPartners. The company has 3386 active competitors, including 1136 funded and 785 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of antibody-drug conjugates for the treatment of cancer. The company has proprietary technology platforms which include the Tub-tag conjugation platform, P5 conjugation platform, and Topoisomerase-I inhibitor platform to develop antibody-drug conjugates for solid and hematological tumors. It offers TUB-040 for ovarian and non-small cell lung cancer. TUB-030, TUB-050, and TUB-060 for solid tumors.

Website: tubulis.com
Social

Key Metrics

Founded Year

2015

Location

Munich, Germany

Stage

Acquired

Total Funding

$615M in 6 rounds

Latest Funding Round

Series C, Oct 15, 2025, $*****

Investors

Venrock & 28 more

Ranked

109^th among 3386 active competitors

Employee Count

77 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3083 more

Exit Details

Acquired by Gilead (Apr 07, 2026)

View Tubulis Technologies' full profile

Tubulis Technologies is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Tubulis GmbH CIN: D2601_HRB249942 , Germany, Active	Jul 08, 2019	-	-
Tubulis GmbH CIN: HRB249942 , Germany, Active	Jul 07, 2019	-	-

Tubulis Technologies got acquired by Gilead on Apr 07, 2026 at an acquisition amount of $*****.

Click here to take a look at Tubulis Technologies's acquisition in detail

Tubulis Technologies has raised a total funding of $615M over 6 rounds. Its latest funding round was a Series C round on Oct 15, 2025 for $*****. 16 investors participated in its latest round. Tubulis Technologies has 24 institutional investors and 5 angel investors.

Here is the list of recent funding rounds of Tubulis Technologies:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 15, 2025	8558732	Series C	9080208	2364969	6675262	5913406
Mar 14, 2024	9605674	Series B	7134114	5864184	2141292	Deep Track Capital & 10 more
Aug 16, 2022	2917512	Grant (prize money)	8419362	4186957	2702248	Falling-Walls

Access funding benchmarks and valuations. Sign up today!

View details of Tubulis Technologies's funding rounds and investors

The founders of Tubulis Technologies are Dominik Schumacher and Jonas Helma-Smets. Dominik Schumacher is the CEO of Tubulis Technologies.

Here are the details of Tubulis Technologies' key team members:

Dominik Schumacher: Co-Founder & CEO of Tubulis Technologies.
Contact Info: 1 email address
Jonas Helma-Smets: Co-Founder & CSO of Tubulis Technologies.

View details of Tubulis Technologies's Founder profiles and Board Members

Tubulis Technologies' employee count trend

Tubulis Technologies has 77 employees as of Aug 26. Here is Tubulis Technologies's employee count trend over the years:

Employee count trend for Tubulis Technologies

Uncover Tubulis Technologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tubulis Technologies include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Tubulis Technologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
109th	Tubulis Technologies 2015, Munich (Germany), Acquired	Developer of antibody-drug conjugates for the treatment of cancer	$615M	Fidelity Investments, Frazier Life Sciences ... & 27 others	62/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Tubulis Technologies's competitors? Click here to see the top ones

Tubulis Technologies has made no investments or acquisitions yet.

Here is the latest report on Tubulis Technologies's sector:

Free

Oncology - Sector Report

Edition: August, 2026 (74 Pages)

View all reports related to Tubulis Technologies

Media has covered Tubulis Technologies for a total of 18 events in the last 1 year, 9 of them have been about company updates and 2 about people movement.